placebo) did not achieve significance in the Japanese phase 2/3 trial, 14 the Japanese phase 3 trial found that condoliase treatment resulted in significantly greater improvements in SF-36 PCS versus placebo at weeks 13 and 52. 17 Consistent with the Japanese phase 3 study, 17 the impact of condoliase on the mental component of the SF-36 (ie, MCS) was minimal.
← all excerpts
Impact of Condoliase on Health-related Quality of Life in Participants With Radicular Leg Pain Associated With Lumbar Disk Herniation: Results From a United States Phase 3 Clinical Trial.
1
—
—